Keino Hiroshi, Okada Annabelle A, Watanabe Takayo, Nakayama Makiko, Nakamura Tomoko
a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.
b Department of Ophthalmology , Toyama University School of Medicine , Toyama , Japan.
Ocul Immunol Inflamm. 2017 Feb;25(1):46-51. doi: 10.1080/09273948.2016.1239746. Epub 2016 Oct 21.
To compare the efficacy of infliximab (IFX) on refractory uveoretinitis between Behçet disease (BD) patients with short duration (≤18 months, n = 6) versus long duration (>18 months, n = 7) of their ocular disease.
Records of 13 BD patients treated with IFX for 24 months were retrospectively reviewed.
Frequency of ocular attacks decreased with IFX treatment in both groups, with no significant difference. Retinal and disc vascular leakage scores also decreased in both groups, however was significantly lower in the short-duration group. Percentage of eyes with a best-corrected visual acuity (BCVA) of 1.0 or better at year 2 was 100% in the short-duration and 21% in the long-duration group.
Induction of early remission using IFX appeared to be more effective in reducing background vascular leakage and in maintaining good visual acuity in BD patients.
比较英夫利昔单抗（IFX）对病程较短（≤18个月，n = 6）与病程较长（>18个月，n = 7）的白塞病（BD）患者难治性葡萄膜视网膜炎的疗效。
回顾性分析13例接受IFX治疗24个月的BD患者的记录。
两组患者经IFX治疗后眼部发作频率均降低，无显著差异。两组患者的视网膜和视盘血管渗漏评分也均降低，但短病程组显著更低。在第2年时，最佳矫正视力（BCVA）为1.0或更好的眼的百分比，短病程组为100%，长病程组为21%。
使用IFX诱导早期缓解似乎在减少BD患者的背景血管渗漏和维持良好视力方面更有效。
